The technology aims to enable blood drawing, collection and sample stabilization in a single device. It also aims to allow for room temperature shipping and easy processing.
Lee McCracken will serve as Drawbridge Health CEO. He is equipped with more than 25 years of experience in the biotech, pharmaceuticals and diagnostics industries. He previously served as CEO of Gensignia Life Sciences, a molecular diagnostics company.
“The current sample testing process is inconvenient and challenging for patients and medical providers, alike,” said Mr. McCracken. “It requires clinical processing equipment, often a technician specifically trained to draw blood, plus a trip to the doctor’s office or hospital. By combining world class GE technology and a talented founding team to address an important market need, Drawbridge Health is well positioned to transform diagnostic testing for healthcare stakeholders, testing laboratories, patients and consumers.”
More articles on health IT:
HHN names 1st non-US hospital to ‘Most Wired’ list
Viewpoint: The ‘unicorn’ test doesn’t work for digital health startups
CMO for England: Genomics will shorten ‘diagnostic odyssey’ for patients with rare disease
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
